Have a question about this calculator? Get a detailed answer.
The Panic Disorder Severity Scale (PDSS) is a 7-item clinician-administered rating scale developed by Dr. M. Katherine Shear and colleagues in 1997 at the University of Pittsburgh. It was designed to provide a comprehensive yet efficient measure of panic disorder severity that captures all the major dimensions of the condition, not just the frequency of panic attacks. The PDSS is widely used as the primary outcome measure in clinical trials for panic disorder and as a clinical tool for monitoring treatment response. The seven items assess: (1) frequency of panic attacks, (2) distress during panic attacks, (3) severity of anticipatory anxiety about future attacks, (4) agoraphobic fear and avoidance, (5) interoceptive fear and avoidance (avoidance of activities that produce physical sensations similar to panic), (6) impairment in work functioning, and (7) impairment in social functioning. Each item is rated on a 5-point scale from 0 (none) to 4 (extreme), yielding a total score range of 0 to 28. The PDSS was developed because existing panic disorder measures at the time either assessed only panic attack frequency (ignoring the broader impact of the disorder), were too lengthy for routine clinical use, or conflated panic symptoms with general anxiety. By targeting seven specific dimensions, the PDSS provides a multidimensional severity profile that is clinically informative while remaining brief enough for routine administration. A composite score of 0 to 28 allows tracking of overall improvement, while individual item scores reveal which dimensions are most severely affected. The PDSS has excellent psychometric properties with good internal consistency (alpha = 0.65), high interrater reliability (ICC = 0.87), and strong sensitivity to change in treatment studies. A total score of 8 to 10 is typically considered the threshold for clinically significant panic disorder, and a reduction of 40 percent or more from baseline is considered a clinically meaningful treatment response. The PDSS self-report version (PDSS-SR) allows patients to complete the scale without a clinician, with comparable psychometric properties.
PDSS Total Score = Item 1 + Item 2 + Item 3 + Item 4 + Item 5 + Item 6 + Item 7 Each item rated 0 (none) to 4 (extreme): - Item 1: Panic attack frequency (0 = no attacks to 4 = more than one attack daily) - Item 2: Distress during panic (0 = none to 4 = extreme distress) - Item 3: Anticipatory anxiety (0 = none to 4 = nearly constant worry about attacks) - Item 4: Agoraphobic avoidance (0 = none to 4 = nearly complete avoidance) - Item 5: Interoceptive avoidance (0 = none to 4 = complete avoidance of sensation-producing activities) - Item 6: Work impairment (0 = none to 4 = unable to work) - Item 7: Social impairment (0 = none to 4 = unable to participate in social activities) Worked Example: A 31 year old woman with a 2-year history of panic disorder: 1. Panic frequency: 2-3 full attacks per week = 2 2. Distress during attacks: Extreme, overwhelming terror = 4 3. Anticipatory anxiety: Frequent worry, hypervigilant for symptoms = 3 4. Agoraphobic avoidance: Avoids public transport, shopping malls, theaters = 3 5. Interoceptive avoidance: Avoids exercise, coffee, hot showers due to triggering sensations = 3 6. Work impairment: Moderate, has missed several days and avoids presentations = 2 7. Social impairment: Significant, avoids most social gatherings = 3 PDSS Total = 2 + 4 + 3 + 3 + 3 + 2 + 3 = 20 Interpretation: A score of 20 out of 28 indicates severe panic disorder with prominent agoraphobic and interoceptive avoidance, significant anticipatory anxiety, and moderate to severe functional impairment across work and social domains. First-line treatment with both CBT and an SSRI is strongly indicated.
- 1Establish the Diagnosis of Panic Disorder Before Administering: The PDSS is a severity measure, not a diagnostic screening tool. It should be administered only after panic disorder has been diagnosed according to DSM-5 criteria, which require recurrent unexpected panic attacks (abrupt surges of intense fear or discomfort reaching a peak within minutes) accompanied by at least 4 of 13 defined symptoms, followed by at least one month of persistent worry about additional attacks, worry about the implications or consequences of attacks, or significant behavioral changes related to the attacks. The PDSS should not be used to screen for panic disorder in undiagnosed patients.
- 2Assess Panic Attack Frequency (Item 1): Rate the frequency of panic attacks over the past week (or other defined assessment period). Full panic attacks (reaching peak within minutes with 4 or more symptoms) and limited-symptom attacks (fewer than 4 symptoms) should both be counted but may be tracked separately. Rating: 0 = no panic attacks, 1 = mild (infrequent, approximately once per week or less), 2 = moderate (1-2 per week), 3 = severe (more than 2 per week but not daily), 4 = extreme (daily or nearly daily attacks). The clinician should help the patient distinguish panic attacks from general anxiety episodes, which do not have the abrupt onset and peak characteristics.
- 3Assess Distress During Attacks (Item 2): Rate the level of distress or fear experienced during panic attacks. This dimension is separate from frequency because some patients have frequent attacks with moderate distress (having habituated somewhat) while others have infrequent attacks with extreme terror. Rating: 0 = no distress, 1 = mild (some unpleasant feelings but manageable), 2 = moderate (significant distress but able to tolerate), 3 = severe (intense distress, strong urge to flee), 4 = extreme (overwhelming terror, feeling of dying or losing control). This item captures the subjective emotional intensity of the panic experience.
- 4Assess Anticipatory Anxiety (Item 3): Rate the severity of worry or apprehension about future panic attacks when not currently having one. Anticipatory anxiety is often the most persistent and disabling dimension of panic disorder, continuing between attacks and driving avoidance behavior. Rating: 0 = no anticipatory anxiety, 1 = occasional concern about attacks, 2 = frequent worry about attacks occupying significant time, 3 = pervasive worry that is difficult to control, 4 = nearly constant worry about attacks that is disabling. Patients often describe this as 'fear of the fear' or being constantly on guard for the next attack.
- 5Assess Agoraphobic and Interoceptive Avoidance (Items 4 and 5): Rate agoraphobic avoidance (item 4): the extent to which the patient avoids situations or places where panic attacks have occurred or might occur, including crowds, public transportation, shopping centers, enclosed spaces, or being far from home. Rate interoceptive avoidance (item 5): the extent to which the patient avoids activities that produce physical sensations similar to panic symptoms, such as exercise (rapid heartbeat), coffee (stimulation), hot environments (sweating), emotional movies (arousal), or sexual activity (increased heart rate and breathing). Both items are rated 0-4 from no avoidance to near-complete avoidance.
- 6Assess Functional Impairment (Items 6 and 7): Rate work impairment (item 6): the degree to which panic disorder affects occupational functioning, including missed work days, reduced productivity, avoidance of work tasks, and difficulty with commuting. Rate social impairment (item 7): the degree to which panic disorder affects social relationships and activities, including avoidance of social gatherings, difficulty maintaining friendships, and strain on family relationships. Both are rated 0-4 from no impairment to complete inability to function. For homemakers or retired individuals, rate the equivalent domains of household responsibilities and community involvement.
- 7Calculate Total Score and Develop Treatment Plan: Sum all seven items for the total PDSS score (0-28). Severity ranges: 0-1 = no or minimal panic disorder, 2-5 = borderline to mild, 6-9 = mild to moderate, 10-13 = moderate, 14-18 = moderately severe, 19-28 = severe. For mild cases (PDSS 6-9), CBT alone may be sufficient. For moderate cases (PDSS 10-18), combined CBT and pharmacotherapy (SSRI or SNRI) is recommended. For severe cases (PDSS 19-28), pharmacotherapy should be initiated immediately with concurrent CBT referral, and benzodiazepine bridging therapy may be considered for acute symptom relief while SSRIs take effect. Repeat the PDSS at 4, 8, and 12 weeks to monitor treatment response.
This 26 year old graduate student experiences about one panic attack per week with moderate distress but has developed minimal avoidance and maintains good occupational and social functioning. The PDSS score of 6 indicates mild to moderate severity. CBT focused on cognitive restructuring and interoceptive exposure is recommended as first-line treatment. Pharmacotherapy may not be necessary at this severity level.
This 44 year old accountant has 1-2 panic attacks per week with severe distress, prominent anticipatory anxiety, and significant agoraphobic avoidance that has restricted his daily life. He avoids driving on highways, eating in restaurants, and attending client meetings. Combined treatment with an SSRI (sertraline, starting at 25 mg and titrating to 100-150 mg) and CBT with a specific focus on graduated exposure therapy for agoraphobic situations is recommended.
This 38 year old woman has daily panic attacks with overwhelming terror, constant anticipatory anxiety, near-complete avoidance of all situations and activities, and total inability to work or socialize. She has become effectively housebound. Immediate pharmacotherapy is essential, with an SSRI as the foundation and short-term benzodiazepine (clonazepam 0.5 mg twice daily) for acute relief while the SSRI takes effect over 4-6 weeks. In-home CBT may be necessary initially if the patient cannot travel to a clinic. Consider day treatment or intensive outpatient programming.
Clinical Trial Primary Outcome Measure: The PDSS is the most frequently used primary outcome measure in randomized controlled trials for panic disorder treatments. It has served as the primary endpoint in landmark trials of SSRIs, SNRIs, benzodiazepines, and cognitive behavioral therapy. The FDA and EMA recognize PDSS response (typically defined as 40 percent or greater reduction from baseline) and remission (total score of 3 or less) as meaningful treatment endpoints. This standardization allows direct comparison of treatment efficacy across studies and informs evidence-based treatment guidelines.
Treatment Response Monitoring in Clinical Practice: Clinicians use serial PDSS assessments to track treatment response and guide clinical decisions. A typical monitoring schedule involves baseline PDSS at treatment initiation, repeat assessment at 4 weeks (to evaluate initial response), 8 weeks (to assess whether to continue, augment, or switch treatment), and 12 weeks (to determine whether the treatment trial is adequate). A PDSS reduction of less than 20 percent by week 4 may predict inadequate response to the current treatment, prompting earlier consideration of treatment modification rather than waiting the full 12 weeks.
Stepped Care Treatment Allocation: In stepped care models for panic disorder, the PDSS helps allocate patients to appropriate treatment intensity levels. Patients with mild PDSS scores (6-9) may begin with guided self-help or computerized CBT. Those with moderate scores (10-17) are typically offered individual CBT, pharmacotherapy, or their combination. Severe scores (18-28) may warrant intensive outpatient programming, combined treatment with immediate pharmacotherapy initiation, or consideration of residential treatment for the most severely affected and functionally impaired patients.
Disability and Functional Capacity Assessment: The PDSS is used in occupational health and disability evaluations to objectively document the functional impact of panic disorder. Items 6 and 7, which directly assess work and social impairment, provide standardized data for determining whether work accommodations, disability leave, or vocational rehabilitation are warranted. Serial PDSS scores can also document improvement during treatment, supporting return-to-work planning. The multidimensional nature of the PDSS is particularly useful because it demonstrates that panic disorder's functional impact extends beyond attack frequency to include avoidance and anticipatory anxiety.
When panic attacks occur exclusively in the context of another disorder (social
When panic attacks occur exclusively in the context of another disorder (social anxiety, PTSD, specific phobia), the PDSS may not be the appropriate severity measure. For example, a patient who has panic attacks only when speaking in public has social anxiety disorder, not panic disorder, and should be assessed with the Liebowitz Social Anxiety Scale or Social Phobia Inventory rather than the PDSS. The PDSS is appropriate only when the patient meets DSM-5 criteria for panic disorder (recurrent unexpected panic attacks with persistent worry about attacks or behavioral changes). For patients with comorbid medical conditions that produce panic-like symptoms (hyperthyroidism, cardiac arrhythmias, pheochromocytoma, asthma, vestibular disorders), the PDSS should be administered after medical causes have been evaluated and addressed. A patient whose panic attacks are caused by undiagnosed paroxysmal supraventricular tachycardia needs cardiology referral, not CBT for panic disorder. Conversely, many patients with panic disorder undergo extensive medical workups for their physical symptoms before receiving a correct psychiatric diagnosis. In pregnancy, panic disorder management requires special consideration because both untreated panic disorder and some pharmacotherapies carry risks. The PDSS helps quantify severity to inform the risk-benefit analysis of treatment options. For mild panic disorder in pregnancy (PDSS less than 10), CBT alone may be sufficient and avoids medication exposure. For moderate to severe panic disorder (PDSS 10 or higher), the risks of untreated panic disorder to both mother and fetus (increased cortisol, preterm labor risk, depression comorbidity) may justify pharmacotherapy, with SSRIs (particularly sertraline) having the most reassuring safety data in pregnancy.
| PDSS Score | Severity | Recommended First-Line Treatment | Expected Response Timeline | Monitoring Schedule |
|---|---|---|---|---|
| 0-1 | No/minimal | No treatment needed | N/A | Annual screening |
| 2-5 | Borderline/mild | Psychoeducation, self-help CBT | 4-8 weeks | Monthly |
| 6-9 | Mild to moderate | Individual CBT | 8-12 weeks | Every 4 weeks |
| 10-13 | Moderate | CBT + consider SSRI | 8-12 weeks | Every 2-4 weeks |
| 14-18 | Moderately severe | CBT + SSRI combination | 8-12 weeks | Every 2 weeks initially |
| 19-28 | Severe | SSRI + short-term benzodiazepine + CBT | 4-12 weeks | Weekly initially |
What is the difference between a full panic attack and a limited-symptom attack?
A full panic attack involves an abrupt surge of intense fear or discomfort accompanied by 4 or more of the 13 DSM-5 panic symptoms (palpitations, sweating, trembling, shortness of breath, choking sensation, chest pain, nausea, dizziness, chills or heat sensations, paresthesias, derealization, fear of losing control, fear of dying). A limited-symptom attack has the same abrupt onset and peak characteristics but involves fewer than 4 symptoms. Both types should be counted when scoring PDSS item 1, though some clinicians track them separately because limited-symptom attacks often indicate partial treatment response.
Can panic disorder be cured, or is it a chronic condition?
With appropriate treatment, many patients achieve full remission (PDSS score of 3 or less) and remain well long-term. CBT for panic disorder has the strongest evidence for sustained improvement, with approximately 75 to 85 percent of patients achieving panic-free status after 12 sessions and approximately 70 percent maintaining these gains at 2-year follow-up. SSRIs also produce high response rates but have higher relapse rates upon discontinuation (approximately 25-50 percent). The combination of CBT and medication may offer the best long-term outcomes. However, approximately 20 to 30 percent of patients have a chronic or relapsing course despite treatment.
Why does the PDSS include separate items for agoraphobic and interoceptive avoidance?
These are distinct clinical phenomena that require different treatment approaches. Agoraphobic avoidance involves avoiding external situations (crowded places, enclosed spaces, public transportation) and is treated with in vivo exposure therapy (gradually confronting avoided situations). Interoceptive avoidance involves avoiding internal body sensations that resemble panic symptoms and is treated with interoceptive exposure (deliberately inducing feared sensations through exercises such as hyperventilation, spinning, or breathing through a straw). A patient may improve on one dimension but not the other, and the PDSS captures this differential progress.
How quickly should the PDSS improve with treatment?
With SSRI pharmacotherapy, initial improvement typically begins within 2 to 4 weeks, with maximum benefit at 8 to 12 weeks. A PDSS reduction of at least 20 percent by week 4 is a positive early indicator. With CBT, significant improvement often begins within the first 4 to 6 sessions as patients learn cognitive restructuring and begin exposure exercises. By session 12, most responders have achieved 50 percent or greater reduction in PDSS scores. Combined treatment may produce faster initial improvement than either alone. If there is no meaningful PDSS improvement after 6 weeks of SSRI treatment at adequate dose or 8 sessions of CBT, treatment modification should be considered.
Is the self-report version (PDSS-SR) as reliable as the clinician-administered version?
Yes, the PDSS-SR has been validated against the clinician-administered version with a correlation of r = 0.93, indicating excellent agreement. The PDSS-SR is more practical for routine clinical monitoring and patient tracking between visits. However, the clinician-administered version offers advantages in certain situations: it allows the clinician to probe for clarification, distinguish panic attacks from other anxiety symptoms, and observe the patient's emotional state during the assessment. For clinical trials, the clinician-administered version is preferred for its slightly greater standardization. For routine clinical practice, the PDSS-SR is efficient and reliable.
What role do benzodiazepines play in panic disorder treatment?
Benzodiazepines (particularly alprazolam and clonazepam) provide rapid relief of panic symptoms, often within 30 to 60 minutes for acute attacks. However, they carry significant risks including dependence, tolerance, withdrawal symptoms, cognitive impairment, fall risk in the elderly, and potential for abuse. Current guidelines recommend benzodiazepines only for short-term use (typically 2-4 weeks) as a bridge while SSRIs take effect, or for occasional as-needed use for severe breakthrough attacks. Long-term benzodiazepine use is discouraged because it interferes with the learning processes that underlie CBT effectiveness, is difficult to discontinue, and does not address the underlying pathology.
Pro Tip
When scoring the PDSS, pay special attention to the discrepancy between panic attack frequency (item 1) and anticipatory anxiety (item 3). A patient who has infrequent panic attacks but scores high on anticipatory anxiety may be maintaining low attack frequency through extensive avoidance. This pattern suggests that the underlying disorder is severe despite the apparently low attack rate. Treatment should target anticipatory anxiety and avoidance through exposure therapy, not just panic attack management.
Did you know?
The PDSS was developed partly because panic disorder researchers in the 1990s discovered that simply counting panic attacks was a misleading measure of treatment response. Some patients dramatically reduced their attack frequency but remained severely disabled by anticipatory anxiety and avoidance, essentially trading one prison (frequent attacks) for another (agoraphobic restriction). Conversely, some patients continued to have occasional attacks but greatly improved their functioning and quality of life. This insight that panic disorder severity is multidimensional led to the PDSS becoming the standard that replaced simple panic attack counting.
References
- ›Reliability and Validity of a Brief Instrument for Assessing the Outcomes of Exposure-based Cognitive-Behavioral Therapy: The Panic Disorder Severity Scale - Shear et al., American Journal of Psychiatry, 1997
- ›Multicenter Collaborative Panic Disorder Severity Scale - Shear et al., American Journal of Psychiatry, 2001
- ›Practice Guideline for the Treatment of Patients with Panic Disorder - American Psychiatric Association, 2009
Get Weekly Math Tips
Join 12,000+ subscribers who get calculator tips every week.